ライフサイエンスコーパス: HBIG

1 HBIG and lamivudine combination therapy was administered

2 HBIG mono-therapy was administered to one patient.

3 HBIG was given perioperatively and continued thereafter;

4 Among HBIG recipients, the HBsAg-positive rate was significant

5 nts of HBsAg-positive women receive HepB and HBIG </=12 hours of birth.

6 HepB and HBIG are administered at birth to infants of HBsAg-posit

7 Lamivudine and HBIG combination decreases HBV recurrence 4-fold.

8 combination prophylaxis with lamivudine and HBIG prevented hepatitis B recurrence following liver tr

9 n liver transplantation (LT) recipients, but HBIG is costly and inconvenient to administer, prompting

10 ed or selected by immune pressure exerted by HBIG.

11 who developed recurrent hepatitis B despite HBIG prophylaxis were compared.

12 who developed recurrent hepatitis B despite HBIG prophylaxis, and to determine if these mutations ca

13 nsplantation), it is possible to discontinue HBIG and maintain only long-term nucleos(t)ide analogue(

14 The combination of lamivudine and high-dose HBIG can protect against reinfection of the hepatic allo

15 ion with the use of lamivudine and high-dose HBIG.

16 ificant problem with monotherapy with either HBIG or lamivudine.

17 -negative mothers who were or were not given HBIG.

18 HbsAg- received hepatitis B immune globulin (HBIG) 10,000 IU i.v. daily for 7 days and monthly for 6

19 al and low-dose hepatitis B Immune globulin (HBIG) can effectively prevent HBV recurrence in greater

20 Hepatitis B immune globulin (HBIG) dosing regimens have been poorly defined, utilize

21 Hepatitis B immune globulin (HBIG) has been an integral component of prophylaxis agai

22 Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) r

23 ose intravenous hepatitis B immune globulin (HBIG) treatment with continued lamivudine treatment.

24 unotherapy with hepatitis B immune globulin (HBIG).

25 In this group, HBIG-free prophylaxis cannot be recommended.

26 the second case, hepatitis B immunoglobulin (HBIG) immunoprophylaxis was administered in an attempt t

27 rate, even with hepatitis B immunoglobulin (HBIG) prophylaxis.

28 d lamivudine and hepatitis B immunoglobulin (HBIG) significantly reduced the reinfection rate (P<0.03

29 nd administering hepatitis B immunoglobulin (HBIG) to newborns.

30 ovir, lamivudine+hepatitis B immunoglobulin (HBIG), or lamivudine+entecavir on direct sequencing were

31 infants receive hepatitis B immunoglobulin (HBIG).

32 -positive rate was 15% in HB immunoglobulin (HBIG) recipients (adjusted odds ratio [OR]: 15.63; 95% c

33 eceived hepatitis B-specific immunoglobulin (HBIG) at birth.

34 The efficacy of combination lamivudine/HBIG prophylaxis has not been reported.

35 .796; P=0.020) and combination of lamivudine/HBIG (RR, 0.249; P=0.021) are independently associated w

36 igen (HBeAG)-positive patients required more HBIG to achieve these goals than HBeAG-negative individu

37 Administration of HBIG to infants born to HBeAg-negative mothers did not a

38 s B DNA levels did not predict the amount of HBIG required.

39 We conclude that a very short course of HBIG combined with long-term antiviral therapy is highly

40 e 'a' determinant region and the duration of HBIG therapy.

41 After 6 months, 1000 IU of HBIG was given IM. every 2 weeks for 18 months.

42 ese mutations can revert after withdrawal of HBIG.

43 had a de novo change after the withdrawal of HBIG.

44 bined with a short course (in hospital only) HBIG in liver transplant recipients with HBV DNA less th

45 ed in 1 of 1050 children who did not receive HBIG (.095%).

46 Two control patients who did not receive HBIG had no change in the 'a' determinant in their postt

47 Among students who did not receive HBIG, there was a significantly negative association bet

48 ho did not were more likely to have received HBIG at birth, suggesting that passive antibody may inte

49 V DNA undetectable to 100 IU/mL who received HBIG 5000 IU in anhepatic phase and daily for 5 days tog

50 The single patient who received HBIG monotherapy became HbsAg+ at 6 months.

51 antigen (HBeAg) positivity and who received HBIG off-schedule.

52 in liver transplant recipients who received HBIG prophylaxis.

53 In addition to HBV vaccines, HBIG was given to all 583 children with hepatitis B e an

54 antigen (HBsAg)-positive mothers and whether HBIG administration reduces transmission.

55 patients receiving combination therapy with HBIG and lamivudine have remained HbsAg-.

56 Combination therapy with HBIG and lamivudine may prevent de novo HBV infection in

57 the nucleoside analogue lamivudine, without HBIG, in patients undergoing liver transplantation.